Surgery today · 2002
Expression of vascular endothelial growth factor family messenger RNA in diseased thyroid tissues.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Tanaka Katsuhiro, Kurebayashi Junichi, Sonoo Hiroshi, Otsuki Takemi, Yamamoto Yutaka, Ohkubo Sumiko, Yamamoto Shigeru, Shimozuma Kojiro
Аннотация
PURPOSE: Four different factors have recently been identified in the vascular endothelial growth factor (VEGF)family, namely, VEGF-A, VEGF-B, VEGF-C, and VEGF-D. We investigated the expression of each VEGF gene in diseased thyroids using the multiplex reverse transcription-polymerase chain reaction (RT-PCR) method.
METHODS: The subjects were 61 patients (11 with Graves' disease, 41 with primary papillary carcinoma, and 9 with recurrent papillary carcinoma). A semiquantitative multiplex RT-PCR was designed to compare the RT-PCR products of each VEGF mRNA with beta-actin mRNA products to determine the relative expression.
RESULTS: VEGF-A and VEGF-B mRNA were expressed in all patients, VEGF-C mRNA was expressed in 58 (95.1%), and VEGF-D mRNA was expressed in 28 (46.0%). The expression of VEGF-D mRNA was significantly lower than that of the other VEGF mRNAs. The patients with papillary carcinoma and nodal involvement had significantly higher expression of the VEGF-C mRNA than those without nodal involvement. The expression of VEGF-C mRNA did not directly represent nodal involvement; however, the number of metastatic lymph nodes was positively correlated with the expression of VEGF-C mRNA in the primary tumor.
CONCLUSIONS: To our knowledge, this is the first clinical study on VEGF-B, VEGF-C, and VEGF-D mRNA expression in diseased thyroids. Although VEGF-C mRNA expression was required for nodal involvement, we assume that other factors and mechanisms are also involved.
METHODS: The subjects were 61 patients (11 with Graves' disease, 41 with primary papillary carcinoma, and 9 with recurrent papillary carcinoma). A semiquantitative multiplex RT-PCR was designed to compare the RT-PCR products of each VEGF mRNA with beta-actin mRNA products to determine the relative expression.
RESULTS: VEGF-A and VEGF-B mRNA were expressed in all patients, VEGF-C mRNA was expressed in 58 (95.1%), and VEGF-D mRNA was expressed in 28 (46.0%). The expression of VEGF-D mRNA was significantly lower than that of the other VEGF mRNAs. The patients with papillary carcinoma and nodal involvement had significantly higher expression of the VEGF-C mRNA than those without nodal involvement. The expression of VEGF-C mRNA did not directly represent nodal involvement; however, the number of metastatic lymph nodes was positively correlated with the expression of VEGF-C mRNA in the primary tumor.
CONCLUSIONS: To our knowledge, this is the first clinical study on VEGF-B, VEGF-C, and VEGF-D mRNA expression in diseased thyroids. Although VEGF-C mRNA expression was required for nodal involvement, we assume that other factors and mechanisms are also involved.
Предметные рубрики MeSH
AdolescentAdultAgedAged, 80 and overBiomarkersCarcinoma, PapillaryEndothelial Growth FactorsFemaleGraves DiseaseHumansIntercellular Signaling Peptides and ProteinsLymphokinesMaleMiddle AgedRNA, MessengerReverse Transcriptase Polymerase Chain ReactionStatistics, NonparametricThyroid NeoplasmsVascular Endothelial Growth Factor AVascular Endothelial Growth Factor CVascular Endothelial Growth Factors